Posted on 01/22/2021 5:44:06 PM PST by SeekAndFind
Johnson & Johnson (NYSE: JNJ) is developing one of the most closely watched Covid-19 vaccines, considering that it is a single-dose shot that should be relatively easy to distribute. Here’s a quick rundown on the recent developments for the vaccine. Based on data from the phase 1/2 trials of 805 participants, published on Wednesday, the vaccine generated a long-lasting immune response with 90% of participants generating neutralizing antibodies against the Coronavirus.
Based on these early-stage findings the company expects the vaccine to be more than 70% effective, noting that efficacy could reach “very high levels”. For perspective, the Pfizer and Moderna vaccines, which are being rolled out in the U.S. are over 90% effective. More conclusive efficacy data from J&J’s phase 3 study which has 45,000 volunteers is expected in the coming weeks with the company likely to proceed with emergency approval if the results are favorable.
Separately, there have been reports that the company is seeing some manufacturing delays for the vaccine. While J&J was expected to deliver 12 million doses by the end of February and 100 million by the end of June, it has reportedly fallen behind these goals by as much as two months. [2] As of last September, the company said that it had plans to deliver over a billion doses by the end of 2021.
See our indicative theme of Covid-19 Vaccine stocks – which includes a diverse set of U.S.-based pharma and biotech companies developing Covid vaccines.
(Excerpt) Read more at forbes.com ...
And what is it you understand the Pfizer and Moderna “vaccines” to be “effective” for/against?
The Pfizer and Moderna vaccines are supposed to provide over 90% chance of protection against infection against the Coronavirus. That’s how I understand it.
“I’ll probably take this one. Not the moderna or Pfizer because they use a new technology.”
The mRNA vaccines are new, but the mRNA technology is not. I first read about it in the mid-1990s. The big advance, modifying the nucleotides to block a potentially dangerous over-response by the body’s immune system, was published in 2005.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.